## Recent

% | \$
 Quotes you view appear here for quick access.

# ЕЛН Message Board

• oxledge oxledge Jul 29, 2008 8:17 PM Flag

## ELN's tysabri worth \$30 a share

all one has to do is look at the \$6bill increase in BIIB's market cap this month based on the incredible numbers it gets from its 50% interest in ELN's tysabri......

so now ELN is down 15-20% from \$24 last month before the incredible tysabri news (thats about a \$2 billion mkt cap drop) while BIIB gains \$6 bill from having half of ELN's tysabri....

the mathematics on tysabri with est +100,000 patients in 2010 is for +\$1 eps for ELN and minimum 30 p/e on that earnigns number now...thats \$30 a share....and forget about the value of all of ELN's other drugs under development

SortNewest  |  Oldest  |  Most Replied Expand all replies
• < look at the \$6 billion increase in BIIB's market cap this month .... it gets from its 50% interest in tysabri .... mathematics on tysabri with est +100,000 patients in 2010 is for ELN ...thats \$30 a share >

Do not understand your logic but clearly, there is a mathematical mistake here.

Increase of BIIB value is only \$4 billion, not \$6 billion. Even using your strange logic, instead of \$30 for ELN, the fair price should only be \$20.

Current price is about \$20.

You are a genius.

• all one has to do is look at the \$6bill increase in BIIB's market cap this month based on the incredible numbers it gets from its 50% interest in ELN's tysabri......

so now ELN is down 15-20% from \$24 last month before the incredible tysabri news (thats about a \$2 billion mkt cap drop) while BIIB gains \$6 bill from having half of ELN's tysabri....

the mathematics on tysabri with est +100,000 patients in 2010 is for +\$1 eps for ELN and minimum 30 p/e on that earnigns number now...thats \$30 a share....and forget about the value of all of ELN's other drugs under development

THAT ALONE IS A STRONG BUY

• 1 Reply to wilsonlinda75
• all one has to do is look at the \$6bill increase in BIIB's market cap this month based on the incredible numbers it gets from its 50% interest in ELN's tysabri......

so now ELN is down 15-20% from \$24 last month before the incredible tysabri news (thats about a \$2 billion mkt cap drop) while BIIB gains \$6 bill from having half of ELN's tysabri....

the mathematics on tysabri with est +100,000 patients in 2010 is for +\$1 eps for ELN and minimum 30 p/e on that earnigns number now...thats \$30 a share....and forget about the value of all of ELN's other drugs under development

Hmmmm Great Buying time here

• Ox
Up,up Copaxone!

• Stop playing with yourself. It'll put hair on your palms. ELN is a dog and you know it.

• wwzg@sbcglobal.net wwzg Jul 30, 2008 8:35 AM Flag

all one has to do is look at the \$6bill increase in BIIB's market cap this month based on the incredible numbers it gets from its 50% interest in ELN's tysabri......

so now ELN is down 15-20% from \$24 last month before the incredible tysabri news (thats about a \$2 billion mkt cap drop) while BIIB gains \$6 bill from having half of ELN's tysabri....

the mathematics on tysabri with est +100,000 patients in 2010 is for +\$1 eps for ELN and minimum 30 p/e on that earnigns number now...thats \$30 a share....and forget about the value of all of ELN's other drugs under development

Looking very good

• 1 Reply to wwzg
• wwzg@sbcglobal.net wwzg Jul 30, 2008 9:56 AM Flag

all one has to do is look at the \$6bill increase in BIIB's market cap this month based on the incredible numbers it gets from its 50% interest in ELN's tysabri......

so now ELN is down 15-20% from \$24 last month before the incredible tysabri news (thats about a \$2 billion mkt cap drop) while BIIB gains \$6 bill from having half of ELN's tysabri....

the mathematics on tysabri with est +100,000 patients in 2010 is for +\$1 eps for ELN and minimum 30 p/e on that earnigns number now...thats \$30 a share....and forget about the value of all of ELN's other drugs under development

Looking very good

Get in on the lows

• wwzg@sbcglobal.net wwzg Jul 30, 2008 8:16 AM Flag

all one has to do is look at the \$6bill increase in BIIB's market cap this month based on the incredible numbers it gets from its 50% interest in ELN's tysabri......

so now ELN is down 15-20% from \$24 last month before the incredible tysabri news (thats about a \$2 billion mkt cap drop) while BIIB gains \$6 bill from having half of ELN's tysabri....

the mathematics on tysabri with est +100,000 patients in 2010 is for +\$1 eps for ELN and minimum 30 p/e on that earnigns number now...thats \$30 a share....and forget about the value of all of ELN's other drugs under development

I'd say 32.00

• Your information is flawed. Biogen's market cap is only \$20 billion and Tysabri is not more than half of their total product set in terms of value. Therefore, Elan's share of Tysabri is worth about \$10 billion max. That equates to about \$20 per share.

• Great post. I haven't owned ELN since the FDA hearing days on Tysabri but I'm picking up some this morning.

• wwzg@sbcglobal.net wwzg Jul 30, 2008 12:14 AM Flag

TRADE QUALITY 75%, Good
Good trade quality is a combination of good profit, profit/loss ratio and target potential.

TARGET 1 Price: 36.94 Profit: 9.5% , for a typical rally.
Stop Limit/Trailing Stop Limit: 32.43 Loss: 3.9%
Profit/Loss Ratio: 2.4 : 1 - Fair

TARGET 1 POTENTIAL Excellent, there are 1 resistance areas on the way to Target 1.
Stocks may quickly rise to Targets when there are not many resistance areas blocking the way.

TARGET 1 RESISTANCE +5.1% at 35.46 ± 0.71, type single, strength 5
+9.5% at 36.94 is Target 1

TARGET 2 Price: 38.14 Profit: 13% , Profit/Loss Ratio: 3.3 : 1 - Good

good signals too.

• 1 Reply to wwzg
• wwzg@sbcglobal.net wwzg Jul 30, 2008 7:44 AM Flag

TRADE QUALITY 75%, Good
Good trade quality is a combination of good profit, profit/loss ratio and target potential.

TARGET 1 Price: 36.94 Profit: 9.5% , for a typical rally.
Stop Limit/Trailing Stop Limit: 32.43 Loss: 3.9%
Profit/Loss Ratio: 2.4 : 1 - Fair

TARGET 1 POTENTIAL Excellent, there are 1 resistance areas on the way to Target 1.
Stocks may quickly rise to Targets when there are not many resistance areas blocking the way.

TARGET 1 RESISTANCE +5.1% at 35.46 ± 0.71, type single, strength 5
+9.5% at 36.94 is Target 1

TARGET 2 Price: 38.14 Profit: 13% , Profit/Loss Ratio: 3.3 : 1 - Good

good signals too. .....

0.0000(0.00%)